Compare Dulaglutide (evidence A) and Semaglutide (evidence A) on mechanism, clinical status, safety, and dosing.
Dulaglutide (brand name Trulicity) is a once-weekly GLP-1 receptor agonist developed by Eli Lilly, FDA-approved in September 2014 for type 2 diabetes. It is a…
Semaglutide is an FDA-approved GLP-1 receptor agonist (MW ~4113.6 g/mol, molecular formula C187H291N45O59) with 94% sequence homology to human GLP-1. It is…
Full profiles: Dulaglutide, Semaglutide.